On April 11, 2018, the US Food and Drug Administration made history by granting De Novo authorization to IDx-DR — the first AI system ever approved to provide a diagnostic decision without requiring physician interpretation. This milestone marked the beginning of a new era in autonomous medical AI, and MedicalCloudAIHub.com integrates IDx-DR for all fundus photography workflows involving diabetic patients.
The Scale of Diabetic Eye Disease
Diabetic retinopathy affects approximately 103 million people worldwide and is the leading cause of preventable blindness in working-age adults. Annual fundus photography screening is recommended for all diabetic patients, yet ophthalmologist availability is severely limited in many regions. IDx-DR makes autonomous AI screening deployable in any primary care setting where a non-mydriatic fundus camera is available.
How IDx-DR Works
A trained medical assistant captures two fundus photographs per eye using a compatible non-mydriatic camera. The images are automatically uploaded to IDx-DR, which analyzes them using a deep learning algorithm and returns a binary diagnostic result: positive for more than mild diabetic retinopathy (refer to ophthalmology) or negative (continue annual screening). The entire process takes under one minute.
FDA Pivotal Trial Results
In the pivotal clinical trial submitted to the FDA, IDx-DR achieved 87.2% sensitivity and 90.7% specificity for detecting more than mild diabetic retinopathy across 900 patients at 10 primary care sites — exceeding the predetermined performance thresholds and demonstrating real-world performance across diverse patient populations.
Access IDx-DR via MedicalCloudAIHub
$1,000/month — All 14 AI platforms — contact@medicalcloudaihub.com | SCMDSD LLC, Cheyenne, Wyoming